End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34 ZAR | -1.51% | +1.01% | +10.79% |
May. 31 | Dis-Chem Pharmacies Limited Reports Earnings Results for the Full Year Ended February 29, 2024 | CI |
May. 31 | Transcript : Dis-Chem Pharmacies Limited, 2024 Earnings Call, May 31, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company benefits from high valuations in earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.79% | 1.6B | C | ||
-46.68% | 8.7B | B | ||
-26.89% | 6.57B | B | ||
-5.53% | 6.09B | C+ | ||
+91.60% | 5.11B | C | ||
-3.36% | 4.58B | D- | ||
+1.56% | 4.32B | B | ||
-27.53% | 4.03B | C | ||
+2.28% | 2.96B | B | ||
-20.44% | 2.51B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DCP Stock
- Ratings Dis-Chem Pharmacies Limited